公开(公告)号：US20080166408A1

公开(公告)日：2008-07-10

申请号：US11815326

申请日：2006-02-03

申请人： Joanne Heafield ,  Vincenzo Re

发明人： Joanne Heafield ,  Vincenzo Re

IPC分类号： A61K9/24 ,  A61K31/4436 ,  A61P3/10 ,  A61P25/00 ,  A61P17/00 ,  A61P9/00

CPC分类号： A61K9/209 ,  A61K31/427

摘要： An oral dosage form, such as a bilayer tablet, comprising a first layer of a first composition and a second layer of a second composition, each composition comprising 5-[4-[2-(N-methyl-N-(2 pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione or a pharmaceutically acceptable salt or solvate thereof, (‘the drug’) and a pharmaceutically acceptable carrier therefor, wherein the first and second compositions are arranged to release drug at differing release rates on administration; a process for preparing such a dosage form; and the use of such a dosage form in medicine.

摘要翻译： 包含第一组合物的第一层和第二组合物的第二层的口服剂型，例如双层片剂，每种组合物包含5- [4- [2-（N-甲基-N-（2-吡啶基） 氨基）乙氧基]苄基]噻唑烷-2,4-二酮或其药学上可接受的盐或溶剂合物（“药物”）及其药学上可接受的载体，其中第一和第二组合物被布置成以不同的释放速率释放药物 管理; 制备该剂型的方法; 以及在药物中使用这种剂型。

公开(公告)号：US6162467A

公开(公告)日：2000-12-19

申请号：US370270

申请日：1999-08-09

申请人： Ronald Brown Miller ,  Stewart Thomas Leslie ,  Sandra Therese Antoinette Malkowska ,  Derek Allan Prater ,  Trevor John Knott ,  Joanne Heafield ,  Deborah Challis

发明人： Ronald Brown Miller ,  Stewart Thomas Leslie ,  Sandra Therese Antoinette Malkowska ,  Derek Allan Prater ,  Trevor John Knott ,  Joanne Heafield ,  Deborah Challis

IPC分类号： A61K9/14 ,  A61K9/16 ,  A61K9/20 ,  A61K9/26 ,  A61K9/28 ,  A61K9/48 ,  A61K31/135 ,  A61K31/485

CPC分类号： A61K9/1617 ,  A61K9/1641 ,  A61K9/2013 ,  A61K9/2054 ,  A61K9/2072 ,  A61K9/2077 ,  A61K9/2095 ,  A61K9/2866 ,  A61K31/135 ,  A61K31/485

摘要： A process for the manufacture of particles comprises mechanically working a mixture of a drug and a hydrophobic and/or hydrophilic fusible carrier in a high speed mixture so as to form agglomerates, breaking the agglomerates to give controlled release particles and optionally continuing the mechanical working with the optional addition of a low percentage of the carrier or diluent.

摘要翻译： 用于制造颗粒的方法包括以高速混合物机械加工药物和疏水和/或亲水性熔融载体的混合物，以形成附聚物，破碎附聚物以产生控制释放颗粒，并且可选地继续机械加工 任选地加入低百分比的载体或稀释剂。

公开(公告)号：US5091189A

公开(公告)日：1992-02-25

申请号：US704714

申请日：1991-05-17

申请人： Joanne Heafield ,  Stewart I. Leslie ,  Sandra T. A. Malkowska ,  Philip J. Neale

发明人： Joanne Heafield ,  Stewart I. Leslie ,  Sandra T. A. Malkowska ,  Philip J. Neale

IPC分类号： A61K9/20 ,  A61K9/22 ,  A61K9/52 ,  A61K31/52 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/38

CPC分类号： A61K31/52 ,  A61K9/2013 ,  A61K9/2054

摘要： A controlled release, solid, oral dosage form containing a 3-alkylxanthine, preferably theophylline, at least one hydrophilic or hydrophobic polymer, at least one wax having a melting point between 25.degree. and 90.degree. C. and between 3% and 10% (by weight) water.Preferably the dosage form is a tablet and the water content is between 4% and 9% (by weight). The amount of water present in the dosage form determines the rate of release of the 3-alkylxanthine.

公开(公告)号：US5965163A

公开(公告)日：1999-10-12

申请号：US944106

申请日：1997-09-30

申请人： Ronald Brown Miller ,  Stewart Thomas Leslie ,  Sandra Therese Antoinette Malkowska ,  Derek Allan Prater ,  Trevor John Knott ,  Joanne Heafield ,  Deborah Challis

发明人： Ronald Brown Miller ,  Stewart Thomas Leslie ,  Sandra Therese Antoinette Malkowska ,  Derek Allan Prater ,  Trevor John Knott ,  Joanne Heafield ,  Deborah Challis

IPC分类号： A61K9/14 ,  A61K9/16 ,  A61K9/20 ,  A61K9/26 ,  A61K9/28 ,  A61K9/48 ,  A61K31/135 ,  A61K31/485

CPC分类号： A61K9/1617 ,  A61K31/135 ,  A61K31/485 ,  A61K9/1641 ,  A61K9/2013 ,  A61K9/2054 ,  A61K9/2072 ,  A61K9/2077 ,  A61K9/2095 ,  A61K9/2866

摘要： A process for the manufacture of particles comprises mechanically working a mixture of a drug and a hydrophobic and/or hydrophilic fusible carrier in a high speed mixture so as to form agglomerates, breaking the agglomerates to give controlled release particles and optionally continuing the mechanical working with the optional addition of a low percentage of the carrier or diluent.

摘要翻译： 用于制造颗粒的方法包括以高速混合物机械加工药物和疏水和/或亲水性熔融载体的混合物，以形成附聚物，破碎附聚物以产生控制释放颗粒，并且可选地继续机械加工 任选地加入低百分比的载体或稀释剂。

公开(公告)号：US5849240A

公开(公告)日：1998-12-15

申请号：US607852

申请日：1996-02-27

申请人： Ronald Brown Miller ,  Stewart Thomas Leslie ,  Sandra Therese Antoinette Malkowska ,  Derek Allan Prater ,  Treavor John Knott ,  Joanne Heafield ,  Deborah Challis

发明人： Ronald Brown Miller ,  Stewart Thomas Leslie ,  Sandra Therese Antoinette Malkowska ,  Derek Allan Prater ,  Treavor John Knott ,  Joanne Heafield ,  Deborah Challis

IPC分类号： A61K9/14 ,  A61K9/16 ,  A61K9/20 ,  A61K9/26 ,  A61K9/28 ,  A61K9/48 ,  A61K31/135 ,  A61K31/485 ,  B29B9/08 ,  B29C43/02

CPC分类号： A61K9/1617 ,  A61K31/135 ,  A61K31/485 ,  A61K9/1641 ,  A61K9/2013 ,  A61K9/2054 ,  A61K9/2072 ,  A61K9/2077 ,  A61K9/2095 ,  A61K9/2866

摘要： A process for the manufacture of particles comprises mechanically working a mixture of a drug and a hydrophobic and/or hydrophilic fusible carrier in a high speed mixture so as to form agglomerates, breaking the agglomerates to give controlled release particles and optionally continuing the mechanical working with the optional addition of a low percentage of the carrier or diluent.

摘要翻译： 用于制造颗粒的方法包括以高速混合物机械加工药物和疏水和/或亲水性熔融载体的混合物，以形成附聚物，破碎附聚物以产生控制释放颗粒，并且可选地继续机械加工 任选地加入低百分比的载体或稀释剂。

公开(公告)号：US20080226719A1

公开(公告)日：2008-09-18

申请号：US12067382

申请日：2006-09-20

申请人： Allen D. Roses ,  Joanne Heafield ,  Ann M. Saunders

发明人： Allen D. Roses ,  Joanne Heafield ,  Ann M. Saunders

IPC分类号： A61K9/30 ,  A61K31/4436 ,  A61K31/4353 ,  G01N33/53 ,  A61P25/28

CPC分类号： A61K9/5084 ,  A61K9/2072 ,  A61K9/209 ,  A61K9/2846 ,  A61K9/2886 ,  A61K9/5078 ,  A61K31/4439 ,  A61K31/445 ,  G01N33/92 ,  G01N2800/2814 ,  G01N2800/2821 ,  A61K2300/00

摘要： Disclosed is a pharmaceutical composition comprising both rosiglitazone or a pharmaceutically acceptable salt thereof and donepezil or a pharmaceutically acceptable salt thereof which is of use in the treatment or prophylaxis of Alzheimer's disease or other dementias and mild cognitive impairment. Also disclosed is an oral dosage forms comprising rosiglitazone or a pharmaceutically acceptable salt thereof and donepezil or a pharmaceutically acceptable salt thereof.

摘要翻译： 公开了一种药物组合物，其包含罗格列酮或其药学上可接受的盐和多奈哌齐或其药学上可接受的盐，其用于治疗或预防阿尔茨海默病或其他痴呆症和轻度认知障碍。 还公开了包含罗格列酮或其药学上可接受的盐和多奈哌齐或其药学上可接受的盐的口服剂型。

公开(公告)号：US4867985A

公开(公告)日：1989-09-19

申请号：US162640

申请日：1988-03-01

申请人： Joanne Heafield ,  Stewart T. Leslie ,  Sandra T. A. Malkowska ,  Philip J. Neale

发明人： Joanne Heafield ,  Stewart T. Leslie ,  Sandra T. A. Malkowska ,  Philip J. Neale

IPC分类号： A61K9/16 ,  A61K9/26 ,  A61K9/56 ,  A61K9/62 ,  A61K47/00 ,  A61K47/10 ,  A61K47/26 ,  A61K47/38

CPC分类号： A61K9/1652

摘要： A controlled release pharmaceutical composition contains a number of spheroids, the spheroids containing a water-insoluble drug dispersed in a controlled release matrix. The matrix contains between 70% and 99.5% (by weight) of microcrystalline cellulose, between 0.5% and 4% (by weight) of a cellulose derivative and, optionally, up to 26% of a sugar or a sugar alcohol.The water insoluble drug must dissolve in water (pH 5) at 20.degree. C. to a concentration of less than 1.0 mg ml-1, preferably less than 0.5 mg ml-1. Preferred drugs are non-steroidal anti-inflammatory agents, especially fenprofen calcium, ibuprofen, ketoprofen, naproxen, diclofenac sodium, fenbufen, flurbiprofen, indomethancin, oxyphenbutazone, phenylbutazone or piroxicam.

公开(公告)号：US6143328A

公开(公告)日：2000-11-07

申请号：US264399

申请日：1999-03-08

申请人： Joanne Heafield ,  Trevor John Knott ,  Stewart Thomas Leslie ,  Sandra Therese Antoinette Malkowska ,  Ronald Brown Miller ,  Derek Allan Prater ,  Kevin John Smith

发明人： Joanne Heafield ,  Trevor John Knott ,  Stewart Thomas Leslie ,  Sandra Therese Antoinette Malkowska ,  Ronald Brown Miller ,  Derek Allan Prater ,  Kevin John Smith

IPC分类号： A61K9/16 ,  A61K9/20 ,  A61K9/26 ,  A61K9/28 ,  A61K31/135 ,  A61K31/485 ,  A61K9/14 ,  A61K9/52

CPC分类号： A61K31/485 ,  A61K31/135 ,  A61K9/1617 ,  A61K9/2013 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2095 ,  A61K9/2866

摘要： Sustained release pharmaceutical formulations containing morphine, or a pharmaceutically acceptable salt thereof, as active ingredient, suitable for administration on a once daily basis, are disclosed. In a first aspect, an orally administrable sustained release unit dosage form gives a peak plasma level at 1.0 to 6 hours after administration. In a second aspect, the formulation provides a W.sub.50 for the M-6-G metabolite for morphine of between 4 and 12 hours. A third aspect concerns the pharmaceutical unit dosage form obtained by compressing multiparticulates comprising a pharmaceutically active substance in a matrix of hydrophobic fusible material having a melting point of from 35 to 150.degree. C.

摘要翻译： 公开了含有吗啡或其药学上可接受的盐作为活性成分的持续释放药物制剂，其适用于每天一次给药。 在第一方面，口服给药的持续释放单元剂型在给药后1.0至6小时给出峰值血浆水平。 在第二方面，所述制剂为4-50小时的吗啡的M-6-G代谢产物提供W50。 第三方面涉及通过将包含药物活性物质的多颗粒压缩在熔点为35-150℃的疏水性可熔材料的基质中获得的药物单位剂型。

公开(公告)号：US5891471A

公开(公告)日：1999-04-06

申请号：US607851

申请日：1996-02-27

申请人： Ronald Brown Miller ,  Stewart Thomas Leslie ,  Sandra Therese Antoinette Malkowska ,  Treavor John Knott ,  Deborah Challis ,  Derek Allan Prater ,  Joanne Heafield

发明人： Ronald Brown Miller ,  Stewart Thomas Leslie ,  Sandra Therese Antoinette Malkowska ,  Treavor John Knott ,  Deborah Challis ,  Derek Allan Prater ,  Joanne Heafield

IPC分类号： A61K9/22 ,  A61K31/135 ,  A61K31/485 ,  A61K9/16 ,  A61K9/52

CPC分类号： A61K31/485 ,  A61K31/135 ,  Y10S514/951

摘要： A process for the manufacture of particles comprises mechanically working a mixture of a drug and a hydrophobic and/or hydrophilic fusible carrier in a high speed mixture so as to form agglomerates, breaking the agglomerates to give controlled release particles and optionally continuing the mechanical working with the optional addition of a low percentage of the carrier or diluent.

摘要翻译： 用于制造颗粒的方法包括以高速混合物机械加工药物和疏水和/或亲水性熔融载体的混合物，以形成附聚物，破碎附聚物以产生控制释放颗粒，并且可选地继续机械加工 任选地加入低百分比的载体或稀释剂。

公开(公告)号：US5879705A

公开(公告)日：1999-03-09

申请号：US843571

申请日：1997-04-18

申请人： Joanne Heafield ,  Trevor John Knott ,  Stewart Thomas Leslie ,  Sandra Therese Antoinette Malkowska ,  Ronald Brown Miller ,  Derek Allan Prater ,  Kevin John Smith

发明人： Joanne Heafield ,  Trevor John Knott ,  Stewart Thomas Leslie ,  Sandra Therese Antoinette Malkowska ,  Ronald Brown Miller ,  Derek Allan Prater ,  Kevin John Smith

IPC分类号： A61K9/16 ,  A61K9/20 ,  A61K9/26 ,  A61K9/28 ,  A61K31/135 ,  A61K31/485

CPC分类号： A61K31/485 ,  A61K31/135 ,  A61K9/1617 ,  A61K9/2013 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2095 ,  A61K9/2866

摘要： Sustained release pharmaceutical formulations containing morphine, or a pharmaceutically acceptable salt thereof, as active ingredient, suitable for administration on a once daily basis, are disclosed. In a first aspect, an orally administrable sustained release unit dosage form gives a peak plasma level at 1.0 to 6 hours after administration. In a second aspect, the formulation provides a W.sub.50 for the M-6-G metabolite for morphine of between 4 and 12 hours. A third aspect concerns the pharmaceutical unit dosage form obtained by compressing multiparticulates comprising a pharmaceutically active substance in a matrix of hydrophobic fusible material having a melting point of from 35.degree. to 150.degree. C.

摘要翻译： 公开了含有吗啡或其药学上可接受的盐作为活性成分的持续释放药物制剂，其适用于每天一次给药。 在第一方面，口服给药的持续释放单元剂型在给药后1.0至6小时给出峰值血浆水平。 在第二方面，所述制剂为4-50小时的吗啡的M-6-G代谢产物提供W50。 第三方面涉及通过将包含药学活性物质的多颗粒压缩在熔点为35至150℃的疏水性可熔材料的基质中获得的药物单位剂型。